Sanofi has said the companies are prepared to roll the shot out before RSV season this fall and do not foresee any challenges meeting demand.
The first shot that protects all infants against respiratory syncytial virus, or RSV, won the unanimous backing of an advisory panel to the Centers for Disease Control and Prevention on Thursday.
Note that this is a monoclonal antibody injection and not a vaccine. This means that it will be way more expensive and protection will only last a few months at most. This is still a good thing for that are young and don't mount great immune responses, but an actual vaccine approved for this age group is still needed.
No this drug is actually approved for prevention and not treatment.
It probably would reduce the chance they would get sick and get natural immunity. However a RSV vaccine for infants is hopefully not far off so they can gain immunity that way.